Ferron Par Pharmaceuticals
Ingredients in every tablet
Each package contains
|ATC Level 1||J - Antiinfectives for systemic use|
|ATC Level 2||J01 - Antibacterials for Systemic Use|
|ATC Level 3||J01M - Quinolone Antibacterials|
18 YEARS OLD AND ABOVE
The recommended dose for moxifloxacin is one 400 mg tablet once daily.
For treatment of skin and soft tissue infections requiring initial intravenous therapy followed by administration of 400 mg moxifloxacin tablet.
No adjustment of dosage is required in elderly patients.
No dosage adjustment is required in patients with impaired renal function (creatinine clearance < 30 ml/minute/1.73m²). Efficacy and safety of moxifloxacin in children and adolescents have not been established.
Moxifloxacin is indicated for the treatment in Adults (≥18 years of age) for the following bacterial infections:
a. Upper respiratory tract infections
Acute exacerbations of chronic bronchitis. (I p.358; II p.1; III p.2; IV p.1; V p.1496)
Community-acquired pneumonia. (I p.358; II p.1; III p.2; IV p.1; V p.1496)
Acute sinusitis. (I p.358; II p.1; III p.2; IV p.1; V p.1496)
b. Skin and soft tissue infections (V p.1497)
Moxifloxacin is indicated for the treatment of the infections caused by bacteria susceptible to moxifloxacin. (II p.1; III p.2; IV p.1)